

PROPOSED AMENDMENT
14184-043001
July 9, 2007

RECEIVED
CENTRAL FAX CENTER
JUL 09 2007

1-19. (Canceled)

20. (Currently amended) A purified peptide consisting of the amino acid sequence:

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) or
a pharmacologically acceptable salt thereof. (p. 61, line 26)

21-79. (Canceled)

80. (New) A purified peptide consisting of the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31).

81. (New) A pharmacologically acceptable salt of a purified peptide
consisting of the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31).

82. (New) A purified peptide comprising the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) or
a pharmacologically acceptable salt thereof, wherein the peptide activates the guanylate
cyclase C receptor. (p. 46-47 – note that MD1000 is SEQ ID NO:31)

83. (New) A purified peptide comprising the amino acid sequence:
Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31),
wherein the peptide activates the guanylate cyclase C receptor.

84. (New) A pharmacologically acceptable salt of a purified peptide
comprising the amino acid sequence:

Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31), wherein the peptide activates the guanylate cyclase C receptor.

85. (New) A pharmaceutical composition comprising the purified peptide of any of claims 20 and 80-84 and a pharmaceutically acceptable carrier or excipient.

86. (New) A pharmaceutical composition comprising:

(a) a purified peptide consisting of the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) or a pharmacologically acceptable salt thereof; and

(b) a pharmaceutically acceptable carrier or excipient.

87. (New) A pharmaceutical composition comprising:

(a) a purified peptide consisting of the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31); and

(b) a pharmaceutically acceptable carrier or excipient.

88. (New) A pharmaceutical composition comprising:

(a) a pharmacologically acceptable salt of a purified peptide consisting of the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31); and

(b) a pharmaceutically acceptable carrier or excipient.

89. (New) A pharmaceutical composition comprising:

(a) a purified peptide comprising the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31) or a pharmacologically acceptable salt thereof; and

(b) a pharmaceutically acceptable carrier or excipient.

90. (New) A pharmaceutical composition comprising:

(a) a purified peptide comprising the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31); and

(b) a pharmaceutically acceptable carrier or excipient.

91. (New) A pharmaceutical composition comprising:

(a) a pharmacologically acceptable salt of a purified peptide comprising the amino acid sequence: Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:31); and

(b) a pharmaceutically acceptable carrier or excipient.

92. (New) A method for increasing intestinal motility in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. (see paragraph starting p. 32, line 27)

93. (New) A method for treating a patient suffering from irritable bowel syndrome, the method comprising administering to the patient an effective of amount of the pharmaceutical composition of claim 85. (p. 3, lines 8-11; p. 2, lines 4-10)

94. (New) The method of claim 93 wherein the patient is suffering from constipation-predominant irritable bowel syndrome. (p. 3, lines 8-11; p. 2, lines 4-10)

95. (New) The method of claim 93 wherein the patient is suffering from alternating-predominant irritable bowel syndrome. (p. 3, lines 8-11; p. 2, lines 4-10)

96. (New) A method for treating constipation in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. (paragraph beginning at line 20 of page 15)

97. (New) The method of claim 96 wherein the patient is suffering from chronic constipation. (paragraph beginning at line 1 of page 15)

98. (New) The method of claim 96 wherein the patient is suffering from idiopathic constipation. (paragraph beginning at line 20 of page 15)

99. (New) The method of claim 96 wherein the patient is suffering from post-operative ileus. **(paragraph beginning at line 20 of page 15)**

100. (New) The method of claim 96 wherein the constipation is caused by opiate use. **(paragraph beginning at line 20 of page 15)**

101. (New) A method for treating functional heartburn in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. **(paragraph beginning at line 1 of page 15)**

102. (New) A method for treating dyspepsia in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. **(paragraph beginning at line 1 of page 15)**

103. (New) A method for treating gastroparesis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. **(paragraph beginning at line 1 of page 15)**

104. (New) A method for treating chronic intestinal pseudo obstruction in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. **(paragraph beginning at line 1 of page 15)**

105. (New) A method for treating Crohn's disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. **(see paragraph starting p. 32, line 27)**

106. (New) A method for treating ulcerative colitis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. **(see paragraph starting p. 32, line 27)**

107. (New) A method for treating inflammatory bowel disease in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. (see paragraph starting p. 32, line 27)

108. (New) A method for treating hypertension in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. (see paragraph starting p. 70, line 6)

109. (New) A method for treating pulmonary hypertension in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. (see paragraph starting p. 68, line 23)

110. (New) A method for treating congestive heart failure in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. (see paragraph starting p. 70, line 6)

111. (New) A method for increasing diuresis in a patient, the method comprising administering to the patient an effective amount of the pharmaceutical composition of claim 85. (see paragraph starting p. 70, line 6)